Cancer Cell
Volume 2, Issue 3, September 2002, Pages 183-192
Journal home page for Cancer Cell

Article
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

https://doi.org/10.1016/S1535-6108(02)00127-7Get rights and content
Under an Elsevier user license
open archive

Abstract

The “BH3-only” proteins of the BCL-2 family require “multidomain” proapoptotic members BAX and BAK to release cytochrome c from mitochondria and kill cells. We find short peptides representing the α-helical BH3 domains of BID or BIM are capable of inducing oligomerization of BAK and BAX to release cytochrome c. Another subset characterized by the BH3 peptides from BAD and BIK cannot directly activate BAX, BAK but instead binds antiapoptotic BCL-2, resulting in the displacement of BID-like BH3 domains that initiate mitochondrial dysfunction. Transduced BAD-like and BID-like BH3 peptides also displayed synergy in killing leukemic cells. These data support a two-class model for BH3 domains: BID-like domains that “activate” BAX, BAK and BAD-like domains that “sensitize” by occupying the pocket of antiapoptotic members.

Cited by (0)